胸部恶性肿瘤的免疫治疗：新的治疗方法，新的希望。
Immunotherapy in Thoracic Malignancies: New Treatment and New Hope.
机构信息
BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada.
出版信息
Curr Oncol. 2022 Feb 2;29(2):834-836. doi: 10.3390/curroncol29020070.
Abstract
Over these last two pandemic years, we have all experienced profound changes in how we practice, how we work, and how we live [...].
摘要
在过去的两年大流行期间，我们所有人都经历了行医方式、工作方式和生活方式的深刻变化。
相似文献
1
Immunotherapy in Thoracic Malignancies: New Treatment and New Hope.
Curr Oncol. 2022 Feb 2;29(2):834-836. doi: 10.3390/curroncol29020070.
2
Emerging Therapies in Thoracic Malignancies.
Surg Oncol Clin N Am. 2020 Oct;29(4):xiii-xiv. doi: 10.1016/j.soc.2020.07.003. Epub 2020 Aug 10.
3
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy.
Clin Lung Cancer. 2018 Sep;19(5):377-386. doi: 10.1016/j.cllc.2018.03.004. Epub 2018 Mar 17.
4
The changing landscape of thoracic malignancies.
Curr Oncol. 2018 Jun;25(Suppl 1):S5-S6. doi: 10.3747/co.25.4099. Epub 2018 Jun 13.
5
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.
Eur Respir J. 2018 Feb 14;51(2). doi: 10.1183/13993003.02072-2017. Print 2018 Feb.
6
Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives.
Expert Opin Ther Pat. 2018 Nov;28(11):813-821. doi: 10.1080/13543776.2018.1528234. Epub 2018 Sep 26.
7
[Proceedings: Granulomatous hepatitis due to BCG during immunotherapy for malignant melanoma].
Arch Fr Mal App Dig. 1975 Apr-May;64(3):287-8.
8
Follow-up of patients with thoracic malignancies.
Surg Oncol Clin N Am. 1999 Apr;8(2):355-69.
9
Slow but real progress in the treatment of thoracic malignancies.
Curr Opin Oncol. 1998 Mar;10(2):119-21. doi: 10.1097/00001622-199803000-00006.
10
The cost of success in the treatment of thoracic malignancies.
Curr Opin Oncol. 1995 Mar;7(2):131-3. doi: 10.1097/00001622-199503000-00006.
本文引用的文献
1
Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review.
Curr Oncol. 2022 Jan 21;29(2):479-489. doi: 10.3390/curroncol29020043.
2
New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer.
Curr Oncol. 2021 Dec 23;29(1):38-55. doi: 10.3390/curroncol29010004.
3
The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer.
Curr Oncol. 2021 Dec 16;28(6):5408-5421. doi: 10.3390/curroncol28060451.
4
The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer-An Overview.
Curr Oncol. 2021 Dec 8;28(6):5227-5239. doi: 10.3390/curroncol28060437.
5
Immunotherapy in the First-Line Setting in Wild-Type NSCLC.
Curr Oncol. 2021 Nov 3;28(6):4457-4470. doi: 10.3390/curroncol28060378.
6
The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma.
Curr Oncol. 2021 Nov 8;28(6):4542-4551. doi: 10.3390/curroncol28060385.
7
Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer.
Curr Oncol. 2021 Nov 14;28(6):4686-4701. doi: 10.3390/curroncol28060395.
8
The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer.
Curr Oncol. 2021 Nov 2;28(6):4392-4407. doi: 10.3390/curroncol28060373.
9
Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Curr Oncol. 2021 Oct 12;28(5):4093-4108. doi: 10.3390/curroncol28050347.
Zotero 插件